0 (0%)		11-11 17:43
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	13.27	1-year :	13.98
Resists	First :	11.36	Second :	11.97
Pivot price	10.73
Supports	First :	10.38	Second :	8.63
MAs	MA(5) :	10.6	MA(20) :	10.91
	MA(100) :	9.42	MA(250) :	9.28
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	20.9	D(3) :	16.7
RSI	RSI(14): 43.8
52-week	High :	11.98	Low :	6.65

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NEX ] has closed above bottom band by 32.5%. Bollinger Bands are 51.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	10.79 - 10.84	10.84 - 10.89
Low:	10.26 - 10.32	10.32 - 10.37
Close:	10.52 - 10.61	10.61 - 10.69

Tue, 11 Nov 2025
Nex-Tech plans to install solar charging tables - Great Bend Tribune

Mon, 10 Nov 2025
Intellia Reports Favorable Phase 1 Data for Nex-Z - TipRanks

Mon, 10 Nov 2025
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Mon, 10 Nov 2025
Intellia (NASDAQ: NTLA) reports 81% NYHA stability at 24 months in nex-z Phase 1 - Stock Titan

Sat, 08 Nov 2025
Patient Treated in Trial for Intellia’s Transthyretin Amyloidosis Gene Editing Therapy Nex-Z Dies - CGTLive®

Fri, 07 Nov 2025
Trial Patient Dies After Receiving CRISPR Gene Therapy - MedPage Today

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	229 (M)
Shares Float	196 (M)
Held by Insiders	12 (%)
Held by Institutions	108.9 (%)
Shares Short	10,370 (K)
Shares Short P.Month	10,940 (K)

EPS	2.69
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.94
Profit Margin	17.5 %
Operating Margin	16.1 %
Return on Assets (ttm)	19.3 %
Return on Equity (ttm)	72.3 %
Qtrly Rev. Growth	12.1 %
Gross Profit (p.s.)	3.3
Sales Per Share	15.97
EBITDA (p.s.)	3.62
Qtrly Earnings Growth	137 %
Operating Cash Flow	707 (M)
Levered Free Cash Flow	281 (M)

PE Ratio	3.94
PEG Ratio	0.1
Price to Book value	2.14
Price to Sales	0.66
Price to Cash Flow	3.42

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.